We are live on ! Find out more
GRCE icon

Grace Therapeutics
GRCE

8 hedge funds and large institutions have $8.52M invested in Grace Therapeutics in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

19,061% more capital inflows, than outflows

Capital inflows: $11.1M | Capital outflows: $58K

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more funds holding

Funds holding: 6 → 8 (+2)

4.43% more ownership

Funds ownership: 0.32% → 4.75% (+4.4%)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Perceptive Advisors
Perceptive Advisors
New York
+$7.23M
2
Intact Investment Management
Intact Investment Management
Quebec, Canada
+$2.73M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.11M
4
EEG
E.E. Geduld
+$42.6K
5
Edge Wealth Management
Edge Wealth Management
New York
+$2.46K

Top Sellers

Rank Fund Capital Flow
1
Virtu KCG Holdings
Virtu KCG Holdings
New York
-$53K
2
UBS
UBS
Switzerland
-$5K

GRCE Hedge Fund Activity: Q4 2013 in Review

8 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2013, worth a combined $8.52M — up 667% from $1.11M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GRCE positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $7.23M. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $53K sold.

  • 8 institutional investors held Grace Therapeutics (GRCE) as of Q4 2013, up from 6 in Q3 2013.
  • Funds reported $8.52M of Grace Therapeutics stock for Q4 2013, up 667% quarter-over-quarter.
  • 4 funds opened new Grace Therapeutics positions in Q4 2013 and 2 closed out, a net change of +2 holders.
  • The largest Grace Therapeutics buyer in Q4 2013 was Perceptive Advisors, an estimated $7.23M added.
  • The largest Grace Therapeutics seller in Q4 2013 was Virtu KCG Holdings, an estimated $53K sold.

Based on aggregated 13F filings for Q4 2013.